ImmunityBio (NASDAQ:IBRX) Stock Price Down 11.5%
ImmunityBio (NASDAQ:IBRX) Stock Price Down 11.5%
ImmunityBio, Inc. (NASDAQ:IBRX – Get Rating) was down 11.5% during mid-day trading on Friday . The company traded as low as $5.68 and last traded at $5.69. Approximately 35,224 shares changed hands during trading, a decline of 97% from the average daily volume of 1,358,237 shares. The stock had previously closed at $6.43.
免疫生物公司(纳斯达克代码：IBRX-GET评级)周五午盘下跌11.5%。该公司股价低至5.68美元，最新报5.69美元。约35,224股股票在交易中易手，较1,358,237股的日均成交量下降了97%。该股此前收盘价为6.43美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
A number of equities analysts have issued reports on IBRX shares. Piper Sandler decreased their price target on ImmunityBio from $20.00 to $10.00 in a research note on Friday, May 27th. Jefferies Financial Group started coverage on ImmunityBio in a research note on Wednesday, August 3rd. They set a "buy" rating and a $8.00 price target for the company.
许多股票分析师已经发布了关于IBRX股票的报告。派珀·桑德勒在5月27日星期五的一份研究报告中将免疫生物的目标价从20.00美元下调至10.00美元。杰富瑞金融集团在8月3日星期三的一份研究报告中开始了对免疫生物的报道。他们为该公司设定了“买入”评级和8.00美元的目标价。
ImmunityBio Stock Performance
免疫生物股票表现
The firm has a 50 day moving average price of $4.46 and a two-hundred day moving average price of $4.48.
该公司的50日移动均线价格为4.46美元，200日移动均线价格为4.48美元。
Institutional Investors Weigh In On ImmunityBio
机构投资者参与免疫生物
About ImmunityBio
关于免疫生物
(Get Rating)
(获取评级)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems.
免疫生物公司是一家临床阶段的生物技术公司，致力于开发补充、利用和放大免疫系统以战胜癌症和传染病的疗法和疫苗。它提供免疫治疗和细胞治疗平台，包括抗体细胞因子融合蛋白、合成免疫调节剂、疫苗技术、自然杀伤细胞和适应性(T细胞)免疫系统。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on ImmunityBio (IBRX)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- 免费获取StockNews.com关于免疫生物的研究报告(IBRX)
- 股市：红海中的三座强国
- 第四季度值得考虑的3家银行
- 有什么办法可以治愈Teladoc股票的问题吗？
- 没有人告诉这三只股票这是下跌的一周
- MarketBeat：回顾一周9/12-9/16
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
获得新闻和免疫评级《生物日报》-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对免疫生物公司和相关公司评级的每日简要摘要。